Maze Therapeutics, Inc.
Maze Therapeutics, Inc. (Nasdaq: MAZE) is a clinical-stage biopharmaceutical company developing small-molecule precision medicines for kidney and metabolic diseases. Its Compass platform uses human genetics and clinical data to identify and characterize disease-associated variants and guide target selection, drug… From the company’s description.
In fiscal 2025, Maze Therapeutics, Inc. reported a net loss of $131.12M. Operations used $111.94M in cash.
Dotted labels explain each measure. is shown separately from the annual figures.
What Maze Therapeutics, Inc. does
In the company’s own words
Maze Therapeutics, Inc. (Nasdaq: MAZE) is a clinical-stage biopharmaceutical company developing small-molecule precision medicines for kidney and metabolic diseases. Its Compass platform uses human genetics and clinical data to identify and characterize disease-associated variants and guide target selection, drug discovery and clinical development. Maze’s wholly owned clinical programs include MZE829, an oral APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease, and MZE782, an oral SLC6A19 inhibitor being developed for phenylketonuria and chronic kidney disease. The company also has research and discovery programs in kidney and metabolic diseases. Partnered programs include MZE001 for Pompe disease, licensed to Shionogi, and programs for amyotrophic lateral sclerosis and frontotemporal dementia licensed to other companies. Maze’s ANGPTL7 glaucoma program is held through its approximately 48%-owned Broadwing venture. The company reported positive topline Phase 2 proof-of-concept results for MZE829 in March 2026 and plans further clinical development of both lead programs. Maze reports its business as a single operating segment. Its website is https://mazetx.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1842295
- SIC
- 2836
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Maze Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Maze Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Maze Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Maze Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Maze Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”